Responses
Infections
Letter
Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity
Compose a Response to This Article
Other responses
No responses have been published for this article.